{"pmid":32425250,"pmcid":"PMC7227595","title":"Pharmacological characteristics of patients infected with SARS-Cov-2 admitted to Intensive Care Unit in South of France.","text":["Pharmacological characteristics of patients infected with SARS-Cov-2 admitted to Intensive Care Unit in South of France.","Therapie","Montastruc, Francois","Romano, Charles","Montastruc, Jean-Louis","Silva, Stein","Seguin, Thierry","Minville, Vincent","Georges, Bernard","Riu-Poulenc, Beatrice","Fourcade, Olivier","32425250"],"journal":"Therapie","authors":["Montastruc, Francois","Romano, Charles","Montastruc, Jean-Louis","Silva, Stein","Seguin, Thierry","Minville, Vincent","Georges, Bernard","Riu-Poulenc, Beatrice","Fourcade, Olivier"],"date":"2020-05-20T11:00:00Z","year":2020,"_id":"32425250","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1016/j.therap.2020.05.005","keywords":["aceis, angiotensin converting enzyme inhibitors","arb, angiotensin ii receptor blockers","angiotensin ii receptor blockers","angiotensin converting enzyme inhibitors","covid-19","covid-19, coronavirus disease 2019","ddp4, dipeptidyl peptidase 4 inhibitors","drugs","glp-1 agonists, glucagon-like peptide-1 receptor agonists","icu, intensive care units","nsaids, non-steroidal anti-inflammatory drugs","non-steroidal anti-inflammatory drugs","renin-angiotensin-aldosterone system","sars-cov-2, severe acute respiratory syndrome coronavirus 2"],"locations":["France"],"countries":["France"],"countries_codes":["FRA|France"],"topics":["Diagnosis","Treatment"],"weight":1,"_version_":1667252837893013505,"score":9.490897,"similar":[{"pmid":32307245,"pmcid":"PMC7129535","title":"Treatment options for COVID-19: The reality and challenges.","text":["Treatment options for COVID-19: The reality and challenges.","An outbreak related to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was first reported in Wuhan, China in December 2019. An extremely high potential for dissemination resulted in the global coronavirus disease 2019 (COVID-19) pandemic in 2020. Despite the worsening trends of COVID-19, no drugs are validated to have significant efficacy in clinical treatment of COVID-19 patients in large-scale studies. Remdesivir is considered the most promising antiviral agent; it works by inhibiting the activity of RNA-dependent RNA polymerase (RdRp). A large-scale study investigating the clinical efficacy of remdesivir (200 mg on day 1, followed by 100 mg once daily) is on-going. The other excellent anti-influenza RdRp inhibitor favipiravir is also being clinically evaluated for its efficacy in COVID-19 patients. The protease inhibitor lopinavir/ritonavir (LPV/RTV) alone is not shown to provide better antiviral efficacy than standard care. However, the regimen of LPV/RTV plus ribavirin was shown to be effective against SARS-CoV in vitro. Another promising alternative is hydroxychloroquine (200 mg thrice daily) plus azithromycin (500 mg on day 1, followed by 250 mg once daily on day 2-5), which showed excellent clinical efficacy on Chinese COVID-19 patients and anti-SARS-CoV-2 potency in vitro. The roles of teicoplanin (which inhibits the viral genome exposure in cytoplasm) and monoclonal and polyclonal antibodies in the treatment of SARS-CoV-2 are under investigation. Avoiding the prescription of non-steroidal anti-inflammatory drugs, angiotensin converting enzyme inhibitors, or angiotensin II type I receptor blockers is advised for COVID-19 patients.","J Microbiol Immunol Infect","Jean, Shio-Shin","Lee, Ping-Ing","Hsueh, Po-Ren","32307245"],"abstract":["An outbreak related to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was first reported in Wuhan, China in December 2019. An extremely high potential for dissemination resulted in the global coronavirus disease 2019 (COVID-19) pandemic in 2020. Despite the worsening trends of COVID-19, no drugs are validated to have significant efficacy in clinical treatment of COVID-19 patients in large-scale studies. Remdesivir is considered the most promising antiviral agent; it works by inhibiting the activity of RNA-dependent RNA polymerase (RdRp). A large-scale study investigating the clinical efficacy of remdesivir (200 mg on day 1, followed by 100 mg once daily) is on-going. The other excellent anti-influenza RdRp inhibitor favipiravir is also being clinically evaluated for its efficacy in COVID-19 patients. The protease inhibitor lopinavir/ritonavir (LPV/RTV) alone is not shown to provide better antiviral efficacy than standard care. However, the regimen of LPV/RTV plus ribavirin was shown to be effective against SARS-CoV in vitro. Another promising alternative is hydroxychloroquine (200 mg thrice daily) plus azithromycin (500 mg on day 1, followed by 250 mg once daily on day 2-5), which showed excellent clinical efficacy on Chinese COVID-19 patients and anti-SARS-CoV-2 potency in vitro. The roles of teicoplanin (which inhibits the viral genome exposure in cytoplasm) and monoclonal and polyclonal antibodies in the treatment of SARS-CoV-2 are under investigation. Avoiding the prescription of non-steroidal anti-inflammatory drugs, angiotensin converting enzyme inhibitors, or angiotensin II type I receptor blockers is advised for COVID-19 patients."],"journal":"J Microbiol Immunol Infect","authors":["Jean, Shio-Shin","Lee, Ping-Ing","Hsueh, Po-Ren"],"date":"2020-04-21T11:00:00Z","year":2020,"_id":"32307245","source":"PubMed","week":"202017|Apr 20 - Apr 26","doi":"10.1016/j.jmii.2020.03.034","keywords":["angiotensin converting enzyme inhibitors","coronavirus disease 2019 (covid-19)","hydroxychloroquine","non-steroidal anti-inflammatory drugs","remdesivir","severe acute respiratory syndrome coronavirus 2 (sars-cov-2)"],"locations":["Wuhan","China","RdRp","Chinese"],"countries":["China"],"countries_codes":["CHN|China"],"e_drugs":["remdesivir","Hydroxychloroquine","Ribavirin","lopinavir-ritonavir drug combination","Azithromycin","Teicoplanin","favipiravir"],"topics":["Treatment"],"weight":1,"_version_":1666138491146207233,"score":98.78758},{"pmid":32405162,"pmcid":"PMC7219423","title":"A study on infectivity of asymptomatic SARS-CoV-2 carriers.","text":["A study on infectivity of asymptomatic SARS-CoV-2 carriers.","Background: An ongoing outbreak of coronavirus disease 2019 (COVID-19) has spread around the world. It is debatable whether asymptomatic COVID-19 virus carriers are contagious. We report here a case of the asymptomatic patient and present clinical characteristics of 455 contacts, which aims to study the infectivity of asymptomatic carriers. Material and methods: 455 contacts who were exposed to the asymptomatic COVID-19 virus carrier became the subjects of our research. They were divided into three groups: 35 patients, 196 family members and 224 hospital staffs. We extracted their epidemiological information, clinical records, auxiliary examination results and therapeutic schedules. Results: The median contact time for patients was four days and that for family members was five days. Cardiovascular disease accounted for 25% among original diseases of patients. Apart from hospital staffs, both patients and family members were isolated medically. During the quarantine, seven patients plus one family member appeared new respiratory symptoms, where fever was the most common one. The blood counts in most contacts were within a normal range. All CT images showed no sign of COVID-19 infection. No severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections was detected in 455 contacts by nucleic acid test. Conclusion: In summary, all the 455 contacts were excluded from SARS-CoV-2 infection and we conclude that the infectivity of some asymptomatic SARS-CoV-2 carriers might be weak.","Respir Med","Gao, Ming","Yang, Lihui","Chen, Xuefu","Deng, Yiyu","Yang, Shifang","Xu, Hanyi","Chen, Zixing","Gao, Xinglin","32405162"],"abstract":["Background: An ongoing outbreak of coronavirus disease 2019 (COVID-19) has spread around the world. It is debatable whether asymptomatic COVID-19 virus carriers are contagious. We report here a case of the asymptomatic patient and present clinical characteristics of 455 contacts, which aims to study the infectivity of asymptomatic carriers. Material and methods: 455 contacts who were exposed to the asymptomatic COVID-19 virus carrier became the subjects of our research. They were divided into three groups: 35 patients, 196 family members and 224 hospital staffs. We extracted their epidemiological information, clinical records, auxiliary examination results and therapeutic schedules. Results: The median contact time for patients was four days and that for family members was five days. Cardiovascular disease accounted for 25% among original diseases of patients. Apart from hospital staffs, both patients and family members were isolated medically. During the quarantine, seven patients plus one family member appeared new respiratory symptoms, where fever was the most common one. The blood counts in most contacts were within a normal range. All CT images showed no sign of COVID-19 infection. No severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections was detected in 455 contacts by nucleic acid test. Conclusion: In summary, all the 455 contacts were excluded from SARS-CoV-2 infection and we conclude that the infectivity of some asymptomatic SARS-CoV-2 carriers might be weak."],"journal":"Respir Med","authors":["Gao, Ming","Yang, Lihui","Chen, Xuefu","Deng, Yiyu","Yang, Shifang","Xu, Hanyi","Chen, Zixing","Gao, Xinglin"],"date":"2020-05-15T11:00:00Z","year":2020,"_id":"32405162","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1016/j.rmed.2020.106026","keywords":["asymptomatic carrier","cdc, chinese center for disease control and prevention","chd, congenital heart disease","covid-19, coronavirus disease 2019","ct, computed tomography","contacts","ed, emergency department","edou, emergency department observation unit","gcdc, guangzhou center for disease control and prevention","iqr, interquartile ranges","infectivity","ppe, personal protective equipment","rt-pcr, reverse transcription-polymerase chain reaction","sars-cov-2","sars-cov-2, severe acute respiratory syndrome coronavirus 2"],"topics":["Prevention"],"weight":1,"_version_":1666950579841138688,"score":83.433205},{"pmid":32425361,"pmcid":"PMC7229744","title":"Efficacy and Safety of Lianhuaqingwen Capsules, a repurposed Chinese Herb, in Patients with Coronavirus disease 2019: A multicenter, prospective, randomized controlled trial.","text":["Efficacy and Safety of Lianhuaqingwen Capsules, a repurposed Chinese Herb, in Patients with Coronavirus disease 2019: A multicenter, prospective, randomized controlled trial.","Background: Coronavirus disease 2019 (Covid-19) has resulted in a global outbreak. Few existing targeted medications are available. Lianhuaqingwen (LH) capsule, a repurposed marketed Chinese herb product, has been proven effective for influenza. Purpose: To determine the safety and efficacy of LH capsule in patients with Covid-19. Methods: We did a prospective multicenter open-label randomized controlled trial on LH capsule in confirmed cases with Covid-19. Patients were randomized to receive usual treatment alone or in combination with LH capsules (4 capsules, thrice daily) for 14 days. The primary endpoint was the rate of symptom (fever, fatigue, coughing) recovery. Results: We included 284 patients (142 each in treatment and control group) in the full-analysis set. The recovery rate was significantly higher in treatment group as compared with control group (91.5% vs. 82.4%, P=0.022). The median time to symptom recovery was markedly shorter in treatment group (median: 7 vs. 10 days, P<0.001). Time to recovery of fever (2 vs. 3 days), fatigue (3 vs. 6 days) and coughing (7 vs. 10 days) was also significantly shorter in treatment group (all P<0.001). The rate of improvement in chest computed tomographic manifestations (83.8% vs. 64.1%, P<0.001) and clinical cure (78.9% vs. 66.2%, P=0.017) was also higher in treatment group. However, both groups did not differ in the rate of conversion to severe cases or viral assay findings (both P>0.05). No serious adverse events were reported. Conclusion: In light of the safety and effectiveness profiles, LH capsules could be considered to ameliorate clinical symptoms of Covid-19.","Phytomedicine","Hu, Ke","Guan, Wei-Jie","Bi, Ying","Zhang, Wei","Li, Lanjuan","Zhang, Boli","Liu, Qingquan","Song, Yuanlin","Li, Xingwang","Duan, Zhongping","Zheng, Qingshan","Yang, Zifeng","Liang, Jingyi","Han, Mingfeng","Ruan, Lianguo","Wu, Chaomin","Zhang, Yunting","Jia, Zhen-Hua","Zhong, Nan-Shan","32425361"],"abstract":["Background: Coronavirus disease 2019 (Covid-19) has resulted in a global outbreak. Few existing targeted medications are available. Lianhuaqingwen (LH) capsule, a repurposed marketed Chinese herb product, has been proven effective for influenza. Purpose: To determine the safety and efficacy of LH capsule in patients with Covid-19. Methods: We did a prospective multicenter open-label randomized controlled trial on LH capsule in confirmed cases with Covid-19. Patients were randomized to receive usual treatment alone or in combination with LH capsules (4 capsules, thrice daily) for 14 days. The primary endpoint was the rate of symptom (fever, fatigue, coughing) recovery. Results: We included 284 patients (142 each in treatment and control group) in the full-analysis set. The recovery rate was significantly higher in treatment group as compared with control group (91.5% vs. 82.4%, P=0.022). The median time to symptom recovery was markedly shorter in treatment group (median: 7 vs. 10 days, P<0.001). Time to recovery of fever (2 vs. 3 days), fatigue (3 vs. 6 days) and coughing (7 vs. 10 days) was also significantly shorter in treatment group (all P<0.001). The rate of improvement in chest computed tomographic manifestations (83.8% vs. 64.1%, P<0.001) and clinical cure (78.9% vs. 66.2%, P=0.017) was also higher in treatment group. However, both groups did not differ in the rate of conversion to severe cases or viral assay findings (both P>0.05). No serious adverse events were reported. Conclusion: In light of the safety and effectiveness profiles, LH capsules could be considered to ameliorate clinical symptoms of Covid-19."],"journal":"Phytomedicine","authors":["Hu, Ke","Guan, Wei-Jie","Bi, Ying","Zhang, Wei","Li, Lanjuan","Zhang, Boli","Liu, Qingquan","Song, Yuanlin","Li, Xingwang","Duan, Zhongping","Zheng, Qingshan","Yang, Zifeng","Liang, Jingyi","Han, Mingfeng","Ruan, Lianguo","Wu, Chaomin","Zhang, Yunting","Jia, Zhen-Hua","Zhong, Nan-Shan"],"date":"2020-05-20T11:00:00Z","year":2020,"_id":"32425361","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1016/j.phymed.2020.153242","keywords":["95%ci, 95% confidence interval","ct, computed tomography","coronavirus disease 2019","covid-19, coronavirus disease 2019","fas, full-analysis set","hr, hazards ratio","lh, lianhuaqingwen","lianhuaqingwen capsule","mers, middle east respiratory syndrome coronavirus","pps, per protocol set","pv, protocol deviation","sars-cov-2, severe acute respiratory syndrome coronavirus 2","conversion rate","symptom recovery"],"locations":["Chinese","Chinese"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Treatment"],"weight":1,"_version_":1667252837994725376,"score":80.467865},{"pmid":32300673,"pmcid":"PMC7161481","title":"Genomic characterization of a novel SARS-CoV-2.","text":["Genomic characterization of a novel SARS-CoV-2.","A new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) associated with human to human transmission and extreme human sickness has been as of late announced from the city of Wuhan in China. Our objectives were to mutation analysis between recently reported genomes at various times and locations and to characterize the genomic structure of SARS-CoV-2 using bioinformatics programs. Information on the variation of viruses is of considerable medical and biological impacts on the prevention, diagnosis, and therapy of infectious diseases. To understand the genomic structure and variations of the SARS-CoV-2. The study analyzed 95 SARS-CoV-2 complete genome sequences available in GenBank, National MicrobiologyData Center (NMDC) and NGDC Genome Warehouse from December-2019 until 05 of April-2020. The genomic signature analysis demonstrates that a strong association between the time of sample collection, location of sample and accumulation of genetic diversity. We found 116 mutations, the three most common mutations were 8782C>T in ORF1ab gene, 28144T>C in ORF8 gene and 29095C>T in the N gene. The mutations might affect the severity and spread of the SARS-CoV-2. The finding heavily supports an intense requirement for additional prompt, inclusive investigations that combine genomic detail, epidemiological information and graph records of the clinical features of patients with COVID-19.","Gene Rep","Khailany, Rozhgar A","Safdar, Muhamad","Ozaslan, Mehmet","32300673"],"abstract":["A new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) associated with human to human transmission and extreme human sickness has been as of late announced from the city of Wuhan in China. Our objectives were to mutation analysis between recently reported genomes at various times and locations and to characterize the genomic structure of SARS-CoV-2 using bioinformatics programs. Information on the variation of viruses is of considerable medical and biological impacts on the prevention, diagnosis, and therapy of infectious diseases. To understand the genomic structure and variations of the SARS-CoV-2. The study analyzed 95 SARS-CoV-2 complete genome sequences available in GenBank, National MicrobiologyData Center (NMDC) and NGDC Genome Warehouse from December-2019 until 05 of April-2020. The genomic signature analysis demonstrates that a strong association between the time of sample collection, location of sample and accumulation of genetic diversity. We found 116 mutations, the three most common mutations were 8782C>T in ORF1ab gene, 28144T>C in ORF8 gene and 29095C>T in the N gene. The mutations might affect the severity and spread of the SARS-CoV-2. The finding heavily supports an intense requirement for additional prompt, inclusive investigations that combine genomic detail, epidemiological information and graph records of the clinical features of patients with COVID-19."],"journal":"Gene Rep","authors":["Khailany, Rozhgar A","Safdar, Muhamad","Ozaslan, Mehmet"],"date":"2020-04-18T11:00:00Z","year":2020,"_id":"32300673","source":"PubMed","week":"202016|Apr 13 - Apr 19","doi":"10.1016/j.genrep.2020.100682","keywords":["blast, basic local alignment search tool","cdc, centers of disease control and prevention","covid-19","covid-19, coronavirus disease 2019","emboss, the european molecular biology open software suite","genomic characterization","mers, middle east respiratory syndrome","mutation","ncbi, national center for biotechnology information","ngdc, national genomics data center","nmdc, national microbiology data center","nsp, nonstructural protein","orf, open reading frame","sars-cov-2","sars-cov-2, severe acute respiratory syndrome coronavirus 2","utr, untranslated region","who, world health organization"],"locations":["Wuhan","China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Mechanism"],"weight":1,"_version_":1666138494795251712,"score":80.09802},{"pmid":32289115,"pmcid":"PMC7128473","title":"Care of patients with liver disease during the COVID-19 pandemic: EASL-ESCMID position paper.","text":["Care of patients with liver disease during the COVID-19 pandemic: EASL-ESCMID position paper.","The coronavirus disease 2019 (COVID-19) pandemic poses an enormous challenge to healthcare systems in affected communities. Older patients and those with pre-existing medical conditions have been identified as populations at risk of a severe disease course. It remains unclear at this point to what extent chronic liver diseases should be considered as risk factors, due to a shortage of appropriate studies. However, patients with advanced liver disease and those after liver transplantation represent vulnerable patient cohorts with an increased risk of infection and/or a severe course of COVID-19. In addition, the current pandemic requires unusual allocation of healthcare resources which may negatively impact the care of patients with chronic liver disease that continue to require medical attention. Thus, the challenge hepatologists are facing is to promote telemedicine in the outpatient setting, prioritise outpatient contacts, avoid nosocomial dissemination of the virus to patients and healthcare providers, and at the same time maintain standard care for patients who require immediate medical attention.","JHEP Rep","Boettler, Tobias","Newsome, Philip N","Mondelli, Mario U","Maticic, Mojca","Cordero, Elisa","Cornberg, Markus","Berg, Thomas","32289115"],"abstract":["The coronavirus disease 2019 (COVID-19) pandemic poses an enormous challenge to healthcare systems in affected communities. Older patients and those with pre-existing medical conditions have been identified as populations at risk of a severe disease course. It remains unclear at this point to what extent chronic liver diseases should be considered as risk factors, due to a shortage of appropriate studies. However, patients with advanced liver disease and those after liver transplantation represent vulnerable patient cohorts with an increased risk of infection and/or a severe course of COVID-19. In addition, the current pandemic requires unusual allocation of healthcare resources which may negatively impact the care of patients with chronic liver disease that continue to require medical attention. Thus, the challenge hepatologists are facing is to promote telemedicine in the outpatient setting, prioritise outpatient contacts, avoid nosocomial dissemination of the virus to patients and healthcare providers, and at the same time maintain standard care for patients who require immediate medical attention."],"journal":"JHEP Rep","authors":["Boettler, Tobias","Newsome, Philip N","Mondelli, Mario U","Maticic, Mojca","Cordero, Elisa","Cornberg, Markus","Berg, Thomas"],"date":"2020-04-15T11:00:00Z","year":2020,"_id":"32289115","source":"PubMed","week":"202016|Apr 13 - Apr 19","doi":"10.1016/j.jhepr.2020.100113","keywords":["ace-i, angiotensin-converting enzyme inhibitor","ace2, angiotensin-converting enzyme 2","aclf, acute-on-chronic liver failure","alt, alanine aminotransferase","ast, aspartate aminotransferase","covid-19, coronavirus disease 2019","egd, esophagogastroduodenoscopy","erc, endoscopic retrograde cholangiography","hcc, hepatocellular carcinoma","meld, model for end-stage liver disease","nafld, non-alcoholic fatty liver disease","nash, non-alcoholic steatohepatitis","nuc, nucleoside analogue","pis, protease inhibitors","rdrp, rna-dependent rna polymerase","sars-cov-2, severe acute respiratory syndrome coronavirus 2","uln, upper limit of normal"],"topics":["Prevention"],"weight":1,"_version_":1666138491384233984,"score":79.50237}]}